157 related articles for article (PubMed ID: 34329741)
41. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
Gorrini C; Baniasadi PS; Harris IS; Silvester J; Inoue S; Snow B; Joshi PA; Wakeham A; Molyneux SD; Martin B; Bouwman P; Cescon DW; Elia AJ; Winterton-Perks Z; Cruickshank J; Brenner D; Tseng A; Musgrave M; Berman HK; Khokha R; Jonkers J; Mak TW; Gauthier ML
J Exp Med; 2013 Jul; 210(8):1529-44. PubMed ID: 23857982
[TBL] [Abstract][Full Text] [Related]
42. Medicine. Squelching progesterone's signal may prevent breast cancer.
Marx J
Science; 2006 Dec; 314(5804):1370. PubMed ID: 17138873
[No Abstract] [Full Text] [Related]
43. Selective progesterone receptor modulators: an update.
Benagiano G; Bastianelli C; Farris M; Brosens I
Expert Opin Pharmacother; 2014 Jul; 15(10):1403-15. PubMed ID: 24787486
[TBL] [Abstract][Full Text] [Related]
44. Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis.
Nee K; Ma D; Nguyen QH; Pein M; Pervolarakis N; Insua-Rodríguez J; Gong Y; Hernandez G; Alshetaiwi H; Williams J; Rauf M; Dave KR; Boyapati K; Hasnain A; Calderon C; Markaryan A; Edwards R; Lin E; Parajuli R; Zhou P; Nie Q; Shalabi S; LaBarge MA; Kessenbrock K
Nat Genet; 2023 Apr; 55(4):595-606. PubMed ID: 36914836
[TBL] [Abstract][Full Text] [Related]
45. A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
Triplett AA; Montagna C; Wagner KU
Neoplasia; 2008 Dec; 10(12):1325-34. PubMed ID: 19048111
[TBL] [Abstract][Full Text] [Related]
46. Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment.
Montero Girard G; Vanzulli SI; Cerliani JP; Bottino MC; Bolado J; Vela J; Becu-Villalobos D; Benavides F; Gutkind S; Patel V; Molinolo A; Lanari C
Breast Cancer Res; 2007; 9(2):R22. PubMed ID: 17341305
[TBL] [Abstract][Full Text] [Related]
47. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.
Calvo V; Beato M
Cancer Res; 2011 May; 71(9):3422-31. PubMed ID: 21531767
[TBL] [Abstract][Full Text] [Related]
48. Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.
Sau A; Lau R; Cabrita MA; Nolan E; Crooks PA; Visvader JE; Pratt MA
Cell Stem Cell; 2016 Jul; 19(1):52-65. PubMed ID: 27292187
[TBL] [Abstract][Full Text] [Related]
49. An in vitro study of the effect of mifepristone and ulipristal acetate on human sperm functions.
Ko JK; Huang VW; Li RH; Yeung WS; Ho PC; Chiu PC
Andrology; 2014 Nov; 2(6):868-74. PubMed ID: 25168311
[TBL] [Abstract][Full Text] [Related]
50. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.
Kumar P; Mukherjee M; Johnson JP; Patel M; Huey B; Albertson DG; Simin K
PLoS Genet; 2012; 8(11):e1003027. PubMed ID: 23173005
[TBL] [Abstract][Full Text] [Related]
51. Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development.
Nelson AL
Expert Opin Investig Drugs; 2015; 24(10):1321-30. PubMed ID: 26289789
[TBL] [Abstract][Full Text] [Related]
52. Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice.
Han SJ; Tsai SY; Tsai MJ; O'Malley BW
Endocrinology; 2007 May; 148(5):2471-86. PubMed ID: 17303655
[TBL] [Abstract][Full Text] [Related]
53. The hyperplastic phenotype in PR-A and PR-B transgenic mice: lessons on the role of estrogen and progesterone receptors in the mouse mammary gland and breast cancer.
Sampayo R; Recouvreux S; Simian M
Vitam Horm; 2013; 93():185-201. PubMed ID: 23810007
[TBL] [Abstract][Full Text] [Related]
54. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration.
Bray K; Gillette M; Young J; Loughran E; Hwang M; Sears JC; Vargo-Gogola T
Breast Cancer Res; 2013; 15(5):R91. PubMed ID: 24074261
[TBL] [Abstract][Full Text] [Related]
55. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.
Ramamoorthy S; Tufail R; Hokayem JE; Jorda M; Zhao W; Reis Z; Nawaz Z
Breast Cancer Res Treat; 2012 Feb; 132(1):97-108. PubMed ID: 21553290
[TBL] [Abstract][Full Text] [Related]
57. CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.
Wiehle R; Lantvit D; Yamada T; Christov K
Cancer Prev Res (Phila); 2011 Mar; 4(3):414-24. PubMed ID: 21119048
[TBL] [Abstract][Full Text] [Related]
58. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
59. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
60. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
